Clovis Oncology, Inc. (CLVS)
| Market Cap | 521.78M |
| Revenue (ttm) | 160.01M |
| Net Income (ttm) | -336.16M |
| Shares Out | 104.25M |
| EPS (ttm) | -3.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $4.85 |
| Previous Close | $5.09 |
| Change ($) | -0.24 |
| Change (%) | -4.72% |
| Day's Open | 5.10 |
| Day's Range | 4.85 - 5.12 |
| Day's Volume | 2,518,229 |
| 52-Week Range | 4.08 - 11.10 |
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2021 financial results on Wednesday, August 4, 2021, before the open of the US financial markets. C...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the appointment of Dr. Ronit Simantov to its Board of Directors, effective today. “I am very pleased to we...
Clovis Oncology Inc. (NASDAQ: CLVS) shares gapped up Monday morning but have since fallen back to trading down on the day. There looks to be no company news acting as a catalyst that moved the share pri...
BOULDER, Colo.--(BUSINESS WIRE)--Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide t...
When future promise meets hype, it's hard to deny the potential.
The biotech is getting the sort of attention that its short-sellers would rather avoid.
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) (the “Company”) today announced partial results and the partial adjournment of its 2021 Annual Meeting of Stockholders (the “Annual M...
Clovis is joining the myriad of other big Reddit-stock winners this morning as retail traders move huge amounts of CLVS stock. The post CLVS Stock: Is a Reddit-Fueled Short Squeeze Brewing for Clovis On...
This unloved biotech is finding new life on social media.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
Clovis Oncology Inc. (NASDAQ: CLVS) is gearing up to present this week at the American Society of Clinical Oncology annual meeting, which runs June 4-8. The company is expected to report updated Phase 1...
Retail traders continue to target high short-squeeze stocks in an effort to boost prices and push out hedge funds all at once. The post Short-Squeeze Stocks: Today's Top 10 Stocks With High Short Intere...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it ma...
Clovis (CLVS) reports lower-than-expected loss for first-quarter 2021. Lower new patient start amid COVID-19 hurts U.S. sales of Rubraca.
Clovis Oncology Inc (NASDAQ: CLVS) is trading higher on Wednesday after the company reported better-than-expected first-quarter earnings. What Happened: Clovis Oncology reported an earnings loss of 64 c...
Clovis (CLVS) delivered earnings and revenue surprises of 11.11% and -15.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2021, and provided an update on the Company's clinical developme...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the Bank of America 2021 Health Care Conference
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2021 financial results on Wednesday, May 5, 2021, before the open of the US financial markets. Clovi...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the n...
The biotech's experimental cancer treatment demonstrated promising results in a clinical trial.
Clovis Oncology Inc. (NASDAQ:CLVS) shares are gaining ground in Friday's session. The jump in the shares comes after a company announcement stating that Rubraca significantly improves progression-free s...
Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis ...
Biotech company Clovis Oncology has shown promising info regarding the treatment of ovarian cancer. CLVS stock has benefitted from the data.
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place toda...
CLVS stock should attract buyers because declining coronavirus cases offer more opportunities to serve cancer patients. But the economic narrative confirms that the bears may have a point in their pessi...
Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.
Shares of Clovis Oncology (NASDAQ:CLVS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 59.12% year over year to ($0.74), which beat the estimate of ...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company's clinic...
The next GME will be hard to find, but these three stocks could be solid candidates for a potential short squeeze. The post 3 Troll-able Stocks That Could Be the Next GME appeared first on InvestorPlace.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, before the open of the...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO GU 2021 Virtual Meeting
Hasbro, Nautilus, Clovis Oncology and XPeng were our top stock trades Tuesday. Let's have a look at the charts to see how they're setting up.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic cast...
Unless they were on another planet last week, everybody saw the gigantic moves in companies with huge short interest.
Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's k...
Despite COVID-19, sales will hit a record for the fourth quarter. Company expecting plenty of milestones concerning its ongoing trials in 2021.
Morgan Stanley, Halliburton, Procter & Gamble and Clovis Oncology were our top stock trades for Wednesday. Now, let's look at the charts.
Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, ...
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
About CLVS
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth f... [Read more...]
| Industry Biotechnology | IPO Date Nov 16, 2011 |
| CEO Patrick Mahaffy | Employees 429 |
| Stock Exchange NASDAQ | Ticker Symbol CLVS |
Financial Performance
In 2020, CLVS's revenue was $164.52 million, an increase of 15.05% compared to the previous year's $143.01 million. Losses were -$369.21 million, -7.79% less than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for CLVS stock is "Hold." The 12-month stock price forecast is 6.35, which is an increase of 30.93% from the latest price.